We are a dedicated team of scientists, drug developers and entrepreneurs, racing to provide new medical possibilities to patients
Robert HabibChief Executive Officer
Robin WrightChief Financial Officer
Troels KochChief Technology Officer
Bríd RyanSenior Vice President, Research
Robert PlaceSenior Vice President, Innovation
Kevin FettesVP, CMC and Quality Operations
Robert joined MiNA as founding Chief Executive Officer in 2013. Robert has overseen MiNA’s growth into a clinical stage company with a pipeline of new medicines and collaborations with leading pharmaceutical partners. During his tenure MiNA has established itself as the leader in RNA activation therapeutics, attracting over $100m of funding. Prior to joining MiNA, Robert held roles in private equity and investment banking. He has a BSc from the University of Bristol and a MBA from Columbia Business School.
Robin was appointed Chief Financial Officer in 2021. He has over three decades of experience in over 250 financing transactions and 170 M&A transactions, with previous CFO roles at listed biopharmaceutical companies Pharming Group NV, Karolinska Development AB and Orexo AB. Prior to this, Robin held senior roles in private equity and investment banking, including Head of European Pharma & Chemicals M&A at Citibank Salomon Smith Barney. He is a Fellow of the Institute of Chartered Accountants in England and Wales. Robin is also non-executive chairman of Vaccitech.
Troels joined MiNA in 2021 and leads chemistry research and strategy. Troels brings over 20 years of leadership in RNA therapeutics research, drug discovery and company building. He previously led RNA therapeutics research at Roche as Chief Technology Officer and VP Research, Roche Innovation Centre Copenhagen. Prior to its acquisition by Roche, Troels held the same role at Santaris where he worked for 11 years and founded its predecessor companies Cureon and Exiqon. Troels has a PhD in Bioorganic Chemistry from the University of Copenhagen.
Bríd joined MiNA in 2021 and is VP, Oncology and Immunology Research. Previously, she spent 14 years at the National Cancer Institute in the USA where she led a team focussed on lung cancer research. She has extensive experience in the design and conduct of studies to advance the understanding and clinical management of cancer across the fields of basic science, immunology, and molecular biology. She has published widely in oncology, precision medicine, and biomarkers. Bríd has a PhD in Cancer Biology and Master of Public Health from University College Dublin.
Rob joined MiNA in November 2023 and leads our platform innovation. Rob is a co-inventor and pioneer of RNAa therapeutics, a field he has advanced for over 15 years. Rob was most recently co-founder and Chief Scientific Officer of Ractigen Therapeutics. Prior to this he held leadership roles in a number of RNA therapeutics ventures. Rob conducted postdoctoral research at NIH, UCSF and the VA Medical Center and has a PhD in Molecular and Cell Biology from the University of Connecticut.
Kevin joined in 2021 to lead Chemistry, Manufacturing and Controls (CMC) and Quality Operations. He has over 20 years of experience in the development and manufacture of RNA oligonucleotide medicines at Nitto Denko Avecia, RXi Pharmaceuticals, Galena Biopharma, Dicerna Pharmaceuticals and most recently as an independent consultant. He gained his PhD in Organic Synthesis from the University of London. Kevin is based in Massachusetts USA.
BOARD OF DIRECTORS
Professor Sir Robert Lechler MD, FRCP, FRCPath, FMedSciIndependent Chairman
Susan Clement DaviesIndependent Director
Dr Gur Roshwalb MD, MBAPartner, aMoon
Robert C. Kopple JD, LLMGeneral Partner, KF Business Ventures
Peter BainsNon Executive Director
Robert Habib MBAChief Executive Officer
Professor Sir Robert Lechler MD, FRCP, FRCPath, FMedSci
Robert has over 40 years of experience in academic medicine, being a recognised leader in biomedical research, management and governance. He has held various leadership roles in a range of hospitals and laboratories. Prior roles also include his Presidency of the Academy of Medical Sciences, Membership of the UK Council for Science and Technology, and Chairmanship of the UK MHRA Clinical Trials Expert Advisory Group. Robert currently sits on the Board of directors at Quell Therapeutics. In 2012, Robert was Knighted in the Queen’s Birthday Honours for his services to academic medicine.
Susan Clement Davies
Susan has over 25 years of finance experience in life sciences and investment banking, including as Managing Director of Equity Capital Markets at Citigroup Global Markets Limited and Managing Director at Torreya Partners LLC. Susan currently sits on the Board of Directors of several life science and technology companies including Scancell Holdings, Science Group and Exploristics. Susan is also an Advisor for Oxford Sciences Enterprises.
Dr Gur Roshwalb MD, MBA
Gur has over 20 years of healthcare industry and finance experience and is currently a Partner at aMoon. Previously Gur held CEO roles at various private and public biotechnology companies, as well as roles in venture capital at Venrock and equity research at Piper Jaffray. Gur undertook his residency training in internal medicine at Mount Sinai Medical Center where he was Chief Resident.
Robert C. Kopple JD, LLM
Bob has practiced law in Los Angeles, CA for more than 40 years in the field of taxation and business law. As an entrepreneur, he has financed more than a dozen small companies including several involved in medical science. Bob currently sits on the Board of Directors of several biotechnology companies including Hibernation Therapeutics, Bioseal and ICL Therapeutics.
Peter serves as a Non Executive Director at MiNA, having previously served as its Chief Business Officer. Peter brings three decades of experience in the global pharmaceutical space. Peter is Group Chief Executive Officer of Biocon (BSE:532523). Prior to this Peter held multiple leadership roles in biopharmaceuticals including Chief Business Officer of MiNA and Chief Executive Officer of Sosei Heptares (TSE:4565). Prior to this Peter held a number of roles over 23 years at GlaxoSmithKline including Head of Global Marketing and Senior VP of Commercial Development for GSK’s International Region. Peter is also Non Executive Chairman of ILC Therapeutics and Non Executive Director of Indivior (LSE:INDV).
Robert Habib MBA
Robert joined MiNA as founding Chief Executive Officer in 2013. Robert has overseen MiNA’s growth into a clinical stage company with a pipeline of new medicines and collaborations with leading pharmaceutical partners. During his tenure MiNA has established itself as the leader in saRNA therapeutics, attracting over $100m of funding. Prior to joining MiNA, Robert held roles in private equity and investment banking. He has a BSc from the University of Bristol and a MBA from Columbia Business School.
SCIENTIFIC ADVISORY BOARD
Deya Corzo MD, FACMGGChief Medical Officer-in-residence, Roivant Sciences
Nagy HabibMiNA Co-Founder; Professor of Surgery at Imperial College London
Declan Doogan MD, FRCPChief Medical Officer, Juvenescence
Antonin de Fougerolles PhDChief Executive Officer, Evox Therapeutics
Hans Huber PhDPrincipal, BioTD Strategies, LLC
Professor John Rossi PhDMiNA Co-Founder; Co-Director, Center for RNA Biology and Therapeutics, City of Hope
Professor Pål Sætrom MSc, DPhilMiNA Co-Founder; Professor of Bioinformatics, NTNU Trondheim
Deya Corzo MD, FACMGG
Deya Corzo is Chief Medical Officer-in-residence at Roivant Sciences. Deya is an expert in drug development, clinical genetics and rare diseases with over two decades of experience in the biotechnology sector. Prior industry experience includes roles as Chief Medical Officer at Sigilon Therapeutics and Sojournix Inc., and senior R&D positions at uniQure and Genzyme Corporation overseeing clinical development programs for rare diseases. Deya is a practicing, board-certified clinical geneticists and pediatrician, as well as a faculty member at Harvard Medical School where she completed postdoctoral research and clinical training.
Nagy is a co-founder and previously Head of R&D of MiNA Therapeutics. For over three decades Nagy has been at the forefront of clinical research and clinical practice in cancer. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He has published widely in gene therapy, stem cell therapy, oligonucleotides, endoscopy and surgery. Nagy is Lead Clinician and Head of the Department of HPB Surgery at Imperial College London.
Declan Doogan MD, FRCP
Declan is Chief Medical Officer of Juvenescence, Chairman of Biohaven Pharmaceuticals and Non Executive Director of Portage Biotech. He has more than 30 years of pharmaceutical industry experience spanning numerous roles including Chief Medical Officer at Amarin Corporation and Senior Vice President and Head of World Development at Pfizer. Declan is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine in the United Kingdom and received his Medical degree from Glasgow University.
Antonin de Fougerolles PhD
Antonin is currently Chief Executive Officer of Evox Therapeutics. Prior to this Antonin held several senior R&D leadership roles including Chief Scientific Officer of Ablynx, Chief Scientific Officer of Moderna Therapeutics and Vice President, Research, Immunology, Metabolic, and Viral Disease at Alnylam Pharmaceuticals. After completing his PhD in Immunology at Harvard University, Antonin was a research fellow at the Wellcome Trust Immunology Unit, University of Cambridge.
Hans Huber PhD
Hans is Principal of BioTD Strategies, LLC, where he advises biotechnology companies and life science investors on preclinical development strategy and evaluation of targeted drug delivery and RNA therapeutics programs and technologies. In addition, Hans is an Adjunct Associate Professor of Systems Pharmacology and Translational Therapeutics and Associate Director of The Center for Targeted Therapeutics and Translational Nanomedicine at the University of Pennsylvania. Previously, Hans held multiple roles in preclinical R&D at Merck & Co., Inc, most recently Distinguished Senior Investigator, RNA Therapeutics. Hans received his PhD in Biochemistry at the ETH Zurich and was a research fellow at Harvard Medical School.
Professor John Rossi PhD
John is Dean Emeritus of the Irell and Manella Graduate School of Biological Sciences and Co-Director of the Center for RNA Biology and Therapeutics at City of Hope’s Beckman Research Institute. He is a pioneer in the field of molecular genetics and in particular small RNA biology. John founded Calando Pharmaceuticals, a wholly owned subsidiary of Arrowhead Research Corporation, and is Scientific Co-Founder of Dicerna Pharmaceuticals. John is Co-Founder of MiNA Therapeutics. In recognition of his major contributions to the field, John was appointed Honorary Board Member of the Oligonucleotide Therapeutics Society.
Professor Pål Sætrom MSc, DPhil
Pål is Professor in Bioinformatics at the Norwegian University of Science and Technology at Trondheim. He develops and applies predictive computational models to gene regulation in a disease setting. Pål is Co-Founder of MiNA Therapeutics and Interagon AS.